KRAS and neoplasm: Low-grade serous tumours express KRAS, BRAF, PTEN, PIK3CA, CTNNB1, ARID1A, and PPP2R1A mutations and belong to the type I pathway, whereas high-grade serous tumours are the most frequent type II tumours and exhibit p53 and BRCA mutations [2].